Table 3.

Target Compounds 3, 4, and 6–9 Circumvent Pgp and βIII-Tubulin Mediated Resistance

	IC50 ± SD (nM)			IC50 ± SD (nM)
compd	SK-OV-3	SK-OV-3 MDR1-M6/6	Rr	HeLa	HeLa WTβIII	Rr
(±)-1·HCla (Lead)	38.6 ± 3.1	44.4 ± 3.2	1.2	37.3 ± 4.1	23.9 ± 1.7	0.6
3	7.7 ± 0.8	8.4 ± 0.4	1.1	9.5 ± 0.8	8.1 ± 0.9	0.9
4	14.5 ± 1.0	18.3 ± 1.0	1.3	15.8 ± 1.4	14.6 ± 1.8	0.9
6	40.3 ± 2.6	71.0 ± 19	1.8	33.8 ± 7.4	35.3 ± 9.9	1.0
7	147.8 ± 2.9	200.0 ± 17.1	1.4	111.1 ± 19.0	115.9 ± 9.8	1.0
8	155.8 ± 15.0	161.9 ± 21.5	1.0	120.5 ± 4.2	159.0 ± 17.6	1.3
9	18.6 ± 0.1	32.1 ± 1.5	1.7	15.7 ± 1.2	14.9 ± 1.9	0.9
paclitaxel	5.0 ± 0.6	1,200 ± 58	240	2.8 ± 0.36	24.0 ± 3.0	8.6
CA-4	5.5 ± 0.5	7.2 ± 1.1	1.3	3.3 ± 0.4	3.3 ± 0.3	1.0

^aResults previously published.²⁵